US 232 probe freezes medical device investment in Costa Rica

The US Section 232 investigation has caused multinational medical device companies to pause new investment decisions in Costa Rica. The probe's uncertainty over potential tariffs or trade restrictions is delaying capital commitments, threatening Costa Rica's key export sector. The scope and outcome of the investigation remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works